Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) research hub

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab Plus Gemcitabine Plus Oxaliplatin (R- GEMOX) Versus R- GEMOX Alone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

This study looks at a new drug combination, Polivy plus R-GEMOX, for adults with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to previous treatments. It compares this combination to R-GEMOX alone, checking for safety and how well it works.